Hernández-Hernández Dulce M, Ornelas-Bernal Laura, Guido-Jiménez Miriam, Apresa-Garcia Teresa, Alvarado-Cabrero Isabel, Salcedo-Vargas Mauricio, Mohar-Betancourt Alejandro, Garcia-Carranca Alejandro
Medical Research Unit in Oncology Diseases, Pathology Department, Oncology Hospital, Centro Médico Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Gynecol Oncol. 2003 Aug;90(2):310-7. doi: 10.1016/s0090-8258(03)00320-2.
Our objective was to determine the association between viral load of high risk human papilloma virus (HPV) using the Hybrid Capture II (HC II) system and cervical intraepithelial neoplasia (CIN) lesion stage.
A total of 182 consecutive women with confirmed diagnoses of CIN 1-3 and 182 healthy women with negative Pap were included. All subjects underwent structured interviews focused on socioeconomic and reproductive factors. HC II testing was used to detect human papilloma virus (HPV) DNA. Viral load was measured by light measurements expressed as relative lights unit (RLU) ratio (specimens/control). Log(10)RLU ratios were categorized for analysis into four groups: negative (</=0); low viral load (0.01-1.0), middle viral load (1.01-2.0), and high viral load (2.0-3.6). Frequencies and association measurement odds ratio (OR) adjusted by unconditional multinomial regression (UMR) were used in analysis.
A total of 75 of 80 (93.7%) patients with CIN 2-3, 82 of 101 (79.4%) with CIN 1, and 36 of 182 (19.8%) controls were positive for HPV DNA. The higher the viral load of HPV DNA infection observed, the higher the probability of being associated with stage of CIN (P <0.001). Association between low viral load HPV and CIN 1 was 16.8 (7.2-39) compared with the highest association observed with high viral load and CIN 2-3 (OR(a) = 365.8, 94.7-1412). Both control and cases in the oldest women presented the highest viral load.
We found high frequencies of HPV DNA in CIN 1 and in CIN 2-3 patients. A clear association between viral load of HPV DNA was determined by HC II assay and CIN stage.
我们的目的是使用第二代杂交捕获法（HC II）系统来确定高危型人乳头瘤病毒（HPV）的病毒载量与宫颈上皮内瘤变（CIN）病变分期之间的关联。
总共纳入了182例经确诊为CIN 1 - 3的连续女性患者以及182例巴氏涂片检查阴性的健康女性。所有受试者均接受了聚焦于社会经济和生殖因素的结构化访谈。采用HC II检测来检测人乳头瘤病毒（HPV）DNA。通过光测量来测定病毒载量，以相对光单位（RLU）比值（标本/对照）表示。将Log(10)RLU比值分为四组进行分析：阴性（≤0）；低病毒载量（0.01 - 1.0）、中等病毒载量（1.01 - 2.0）和高病毒载量（2.0 - 3.6）。分析中使用了经无条件多项回归（UMR）调整的频率和关联测量比值比（OR）。
80例CIN 2 - 3患者中有75例（93.7%）、101例CIN 1患者中有82例（79.4%）以及182例对照中有36例（19.8%）HPV DNA呈阳性。观察到HPV DNA感染的病毒载量越高，与CIN分期相关的可能性就越高（P <0.001）。低病毒载量HPV与CIN 1之间的关联为16.8（7.2 - 39），而高病毒载量与CIN 2 - 3之间观察到的关联最高（OR(a)=365.8，94.7 - 1412）。年龄最大的女性中，对照组和病例组的病毒载量均最高。
我们发现CIN 1和CIN 2 - 3患者中HPV DNA的阳性率较高。通过HC II检测确定了HPV DNA病毒载量与CIN分期之间存在明确关联。
